Thyroid and Antithyroid Drugs
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Liothyronine Sodium(BANM, Rinnm) Potassium Perchlorate
2174 Thyroid and Antithyroid Drugs with methodological limitations. However, a controlled trial of In myxoedema coma liothyronine sodium may be liothyronine with paroxetine could not confirm any advantage of given intravenously in a dose of 5 to 20 micrograms by 3 O additive therapy. slow intravenous injection, repeated as necessary, usu- 1. Aronson R, et al. Triiodothyronine augmentation in the treat- HO I ally at intervals of 12 hours; the minimum interval be- ment of refractory depression: a meta-analysis. Arch Gen Psychi- OH atry 1996; 53: 842–8. tween doses is 4 hours. An alternative regimen advo- 2. Altshuler LL, et al. Does thyroid supplementation accelerate tri- NH2 cates an initial dose of 50 micrograms intravenously cyclic antidepressant response? A review and meta-analysis of I O the literature. Am J Psychiatry 2001; 158: 1617–22. followed by further injections of 25 micrograms every 3. Appelhof BC, et al. Triiodothyronine addition to paroxetine in I 8 hours until improvement occurs; the dosage may the treatment of major depressive disorder. J Clin Endocrinol then be reduced to 25 micrograms intravenously twice Metab 2004; 89: 6271–6. (liothyronine) daily. Obesity. Thyroid drugs have been tried in the treatment of obes- Liothyronine has also been given in the diagnosis of ity (p.2149) in euthyroid patients, but they produce only tempo- NOTE. The abbreviation T3 is often used for endogenous tri-io- hyperthyroidism in adults. Failure to suppress the up- rary weight loss, mainly of lean body-mass, and can produce se- dothyronine in medical and biochemical reports. Liotrix is USAN rious adverse effects, especially cardiac complications.1 for a mixture of liothyronine sodium with levothyroxine sodium. -
Method of Estimating Thyroid Hormone Secretion Rate of Rats and Factors Affecting It
View metadata, citation and similar papers at core.ac.uk brought to you by CORE RESEARCH BULLETIN 969 providedSeptember by University of 1969Missouri: MOspace UNIVERSITY OF MISSOURI-COLUMBIA COLLEGE OF AGRICULTURE AGRICULTURAL EXPERIMENT STATION ELMER R. KIEHL, Director Method of Estimating Thyroid Hormone Secretion Rate of Rats and Factors Affecting It CHARLES W. TURNER (Publication authorized September 25, 1969) COLUMBIA, MISSOURI 2 MISSOURI AGRICULTURAL EXPERIMENT STATION ACKNOWLEDGMENT The writer wishes to express his appreciation to the Directors of the Missouri Agricultural Experiment Station and the chairmen of the Depart ment of Dairy Husbandry for their cooperation and financial support of the project Endocrine-genetic Interrelationship in Milk Secretion. In addi tion, the research reported in this bulletin has been supported by generous grants-in-aid from the United States Atomic Energy Commission since 3 1954, when iodine' ' became available for our research. This support, Con tract No. AT (l l-1)-301, extended until my retirement in 1967. The contract has been extended to my successor, Dr. Ralph R. Ander son, as No. AT(l l-1)-1758, from 1968 to date. I am also indebted to the fine group of graduate students and Post Doctorate Fellows who have worked on this project during the past 15 years. Credit for their contributions are indicated in the citation to the re views of their research. While the primary aim of this project has been the extension of our knowledge of the role of the thyroid gland and its hormones in relation to milk secretion, it has made possible, also, the training of graduate students and research fellows in the field of animal physiology and endocrinology. -
Common Thyroid Disorders
9/7/17 Common Louie Riesch MSN, MPH, RN, ACNS-BC, CDE Thyroid Texas Diabetes and Endocrinology Disorders Anatomy of the Thyroid Gland Hypothalamic-Pituitary-Thyroid Axis Physiology Hypothalamus TRH • TSH reflects tissue thyroid – hormone actions • TSH as an index of Pituitary therapeutic success and – potential toxicity TSH T4 Target Tissues T3 Heart Thyroid Gland Liver T4 T3 TR Bone T4 è T3 Liver CNS 1 9/7/17 Production of T4 and T3 Ê T4 is the primary secretory product of the thyroid gland, which is the only source of T4 Ê The thyroid secretes approximately 100 nmol of T4 per day Ê T3 is derived from 2 processes Ê The total daily production rate of T3 is about 15-30 µg Ê About 80% of circulating T3 comes from deiodination of T4 in peripheral tissues Ê Largely liver and kidneys Ê About 20% comes from direct thyroid secretion Free Hormone Concept Ê Only unbound (free) hormone has metabolic activity and physiologic effects Ê Total hormone concentration Ê Normally is kept proportional to the concentration of carrier proteins Ê Is kept appropriate to maintain a constant free hormone level 2 9/7/17 Drugs and Conditions That Increase Serum T4 and T3 Levels by Increasing TBG Drugs that increase TBG Conditions that increase TBG Ê Oral contraceptives and other Ê Pregnancy sources of estrogen Ê Infectious/chronic active Ê Methadone hepatitis Ê Clofibrate Ê HIV infection Ê 5-Fluorouracil Ê Biliary cirrhosis Ê Heroin Ê Acute intermittent porphyria Ê Tamoxifen Ê Genetic factors Evaluate for thyroid disease Ê All >35 years of age, every 5 years Ê -
Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object. -
Neo-Mercazole
NEW ZEALAND DATA SHEET 1 NEO-MERCAZOLE Carbimazole 5mg tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5mg of carbimazole. Excipients with known effect: Sucrose Lactose For a full list of excipients see section 6.1 List of excipients. 3 PHARMACEUTICAL FORM A pale pink tablet, shallow bi-convex tablet with a white centrally located core, one face plain, with Neo 5 imprinted on the other. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Primary thyrotoxicosis, even in pregnancy. Secondary thyrotoxicosis - toxic nodular goitre. However, Neo-Mercazole really has three principal applications in the therapy of hyperthyroidism: 1. Definitive therapy - induction of a permanent remission. 2. Preparation for thyroidectomy. 3. Before and after radio-active iodine treatment. 4.2 Dose and method of administration Neo-Mercazole should only be administered if hyperthyroidism has been confirmed by laboratory tests. Adults Initial dosage It is customary to begin Neo-Mercazole therapy with a dosage that will fairly quickly control the thyrotoxicosis and render the patient euthyroid, and later to reduce this. The usual initial dosage for adults is 60 mg per day given in divided doses. Thus: Page 1 of 12 NEW ZEALAND DATA SHEET Mild cases 20 mg Daily in Moderate cases 40 mg divided Severe cases 40-60 mg dosage The initial dose should be titrated against thyroid function until the patient is euthyroid in order to reduce the risk of over-treatment and resultant hypothyroidism. Three factors determine the time that elapses before a response is apparent: (a) The quantity of hormone stored in the gland. (Exhaustion of these stores usually takes about a fortnight). -
Effect of Methylthiouracil Administration on Nucleic Acids in Rabbit Thyroid
EFFECT OF METHYLTHIOURACIL ADMINISTRATION ON NUCLEIC ACIDS IN RABBIT THYROID NOBUO SUZUKI* Department of Biochemistry,School of Medicine,University of Nagoya Since the experimental reports by Richter and Clisby (1) and Kennedy (2), it has been demonstrated by many authors that the administration of thiourea and its derivatives produce thyroid enlargement involving hypertrophy and hyperplasia of the epithelial cell and colloid loss in various kinds of animals. Although such substances as antithyroid agents functionally give rise to a total hypothyrosis of the animal (3, 4), the follicular cell morphologically does not show the picture of the resting state, but shows on the contrary a hyperactive state. Thiourea and its derivatives have been shown to exert antithyroidal action through their reducing power and preferential reactivity with iodine, which inhibits the oxidative conversion of iodide to iodine-the first step of hormone synthesis (5, 6) and the formation of diiodotyrosine and also the oxidative coupling of two molecules of diiodotyrosine to one molecule of thyroxine-the second and third step of hormone synthesis (7, 8, etc.). It is generally observed that during the course of thiouracil treatment patients are often led into granulocytopenia and in rare cases even fatal agranulocytosis. This toxic effect was confirmed by animal experiments (9, 10), and Tinacci (11) demonstrated that thiouracil blocks the process of cell division of bone-marrow. On the other hand, according to Du Chaliot (12) a grain of wheat in the presence of methylthiouracil does not germinate or worse yet even sprout, and De Ritis and Scalfi (13) observed partial or complete inhibition of the growth of Staphy- lococci in the culture-medium containing thiourea in proportion to the dose. -
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01 -
Liothyronine Sodium(BANM, Rinnm) Potassium Perchlorate
2174 Thyroid and Antithyroid Drugs with methodological limitations. However, a controlled trial of In myxoedema coma liothyronine sodium may be liothyronine with paroxetine could not confirm any advantage of given intravenously in a dose of 5 to 20 micrograms by 3 O additive therapy. slow intravenous injection, repeated as necessary, usu- 1. Aronson R, et al. Triiodothyronine augmentation in the treat- HO I ally at intervals of 12 hours; the minimum interval be- ment of refractory depression: a meta-analysis. Arch Gen Psychi- OH atry 1996; 53: 842–8. tween doses is 4 hours. An alternative regimen advo- 2. Altshuler LL, et al. Does thyroid supplementation accelerate tri- NH2 cates an initial dose of 50 micrograms intravenously cyclic antidepressant response? A review and meta-analysis of I O the literature. Am J Psychiatry 2001; 158: 1617–22. followed by further injections of 25 micrograms every 3. Appelhof BC, et al. Triiodothyronine addition to paroxetine in I 8 hours until improvement occurs; the dosage may the treatment of major depressive disorder. J Clin Endocrinol then be reduced to 25 micrograms intravenously twice Metab 2004; 89: 6271–6. (liothyronine) daily. Obesity. Thyroid drugs have been tried in the treatment of obes- Liothyronine has also been given in the diagnosis of ity (p.2149) in euthyroid patients, but they produce only tempo- NOTE. The abbreviation T3 is often used for endogenous tri-io- hyperthyroidism in adults. Failure to suppress the up- rary weight loss, mainly of lean body-mass, and can produce se- dothyronine in medical and biochemical reports. Liotrix is USAN rious adverse effects, especially cardiac complications.1 for a mixture of liothyronine sodium with levothyroxine sodium. -
Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services
Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services Australian Statistics on Medicines 1997 i © Commonwealth of Australia 1998 ISBN 0 642 36772 8 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be repoduced by any process without written permission from AusInfo. Requests and enquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601. Publication approval number 2446 ii FOREWORD The Australian Statistics on Medicines (ASM) is an annual publication produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee. Comprehensive drug utilisation data are required for a number of purposes including pharmacosurveillance and the targeting and evaluation of quality use of medicines initiatives. It is also needed by regulatory and financing authorities and by the Pharmaceutical Industry. A major aim of the ASM has been to put comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties. Publication of the Australian data facilitates international comparisons of drug utilisation profiles, and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. The data available in the ASM represent estimates of the aggregate community use (non public hospital) of prescription medicines in Australia. In 1997 the estimated number of prescriptions dispensed through community pharmacies was 179 million prescriptions, a level of increase over 1996 of only 0.4% which was less than the increase in population (1.2%). -
Hyper and Hypothyroidism
Editing File Mnemonic File Endocrine Block Pharmacology team 438 Hyper and Hypothyroidism Objectives: By the end of the lecture , you should know: ● Describe different classes of drugs used in hyperthyroidism and hypothyroidism and their mechanism of action ● Understand their pharmacological effects, clinical uses and adverse effects ● Recognize treatment of special cases such as hyperthyroidism during pregnancy, Graves’ disease and Thyroid Storm and special cases of hypothyroidism such as myxedema coma Color index: Black : Main content Purple: Females’ slides only Red : Important Grey: Extra info or explanation Blue: Males’ slides only Green : Dr. notes Hyperthyroidism Thyroid Function ● Normal amount of thyroid hormones are essential for normal growth and development by maintaining the level of energy metabolism in the tissue. ● Either too little or too much thyroid hormones will bring disorders to the body. Important Functions CVS: increase Growth & Thermoregulation Helps maintain heart rate & development, increase basal metabolic cardiac output especially in the metabolic rate energy balance which increase embryo & brain (BMR) oxygen demand Iodine Importance ● Thyroid hormones are unique biological molecules in that they incorporate iodine1 in their structure ● Adequate iodine intake (diet, water) is required for normal thyroid hormone production ● Major sources of iodine are: iodized salt, iodated bread, dairy products, shellfish ● Minimum requirement: 75 micrograms/day Iodine Metabolism 1 2 3 Iodide taken up by the Dietary iodine -
Thyroid Disorders: a Multi-Disciplined Analysis
Thyroid Disorders: A Multi-Disciplined Analysis Author: Chadwick J. Szylvian Persistent link: http://hdl.handle.net/2345/695 This work is posted on eScholarship@BC, Boston College University Libraries. Boston College Electronic Thesis or Dissertation, 2009 Copyright is held by the author, with all rights reserved, unless otherwise noted. Thyroid Disorders: A Multi-Disciplined Analysis Chadwick Szylvian Advised by Dr. John Wing, Ph. D. Boston College, Biology Department Cover image: “Echography of the thyroid gland”. Courtesy of CARRAT Medical Laboratory Tests Thyroid Disorders: A Multi-Disciplined Analysis Authored by Chadwick Szylvian, Boston College 2009 Introduction 3 I. The Endocrine System and the Thyroid Function 5 The Thyroid 6 II. Physiology The Endocrine System 8 The Thyroid and Coordinated Organs 8 Hyperthyroidism 10 Hypothyroidism 12 Human Development 14 III. Molecular Analysis Hormonal Analysis 19 Cellular Receptors of Thyroid Hormones 19 Non-Receptor, Molecular and Genetic Defects Leading to Thyroid Disorders 23 IV. Clinical Considerations – Testing, Pharmacology, and Systemic Integration Testing 26 Pharmacology 29 Thyroid Disorders and the Pharmaceutical Industry 32 Systemic Ramifications of Abnormal Thyroid Functioning 35 Advancing Treatments 37 Dietary Supplements and Thyroid Disorders 38 V. Closing Author Commentary 39 VI. Figures and Diagrams 40 VII. References 46 2 Introduction Despite weighing barely more than an ounce, the tiny butterfly-shaped thyroid gland is a vital metabolic regulator of the endocrine system. The body depends on this tissue of thyroid cells to produce a unique set of hormone products that perfuse throughout the body to maintain homeostatic metabolic function; the importance of this unassuming collection of cells cannot be underestimated. -
Manual Das Denominações Comuns Brasileiras
MDCB Manual das Denominações Comuns Brasileiras Organizadores Lauro D. Moretto Volume Rosana Mastelaro 16 2013 MDCB Manual das Denominações Comuns Brasileiras Organizadores Lauro D. Moretto Volume Rosana Mastelaro 16 2013 Dados Internacionais de Catalogação na Publicação (CIP) (Câmara Brasileira do Livro, SP, Brasil) MDCB : Manual das Denominações Comuns Brasileiras / coordenadores Lauro D. Moretto, Rosana Mastelaro. -- São Paulo : SINDUSFARMA, 2013. -- (Manuais SINDUSFARMA ; v. 16) 1. Medicamentos - Brasil - Nomenclatura I. Moretto, Lauro D.. II. Mastelaro, Rosana. III. Série. CDD-615.1014 13-03273 NLM-QV-704 Índices para catálogo sistemático: 1. DCB : Denominações Comuns Brasileiras : Ciências farmacêuticas 615.1014 2. Fármacos ou medicamentos : Denominações Comuns Brasileiras : Nomenclatura : Ciências farmacêuticas 615.1014 3. fármacos ou medicamentos : denominações comuns brasileiras : Nomenclatura : Ciências farmacêuticas QV-704 Copyright 2013 Agência Nacional de Vigilância Sanitária Todos os direitos reservados. É permitida a reprodução parcial ou total desta obra, desde que citada a fonte. Manual das Denominações Comuns Brasileiras O SINDUSFARMA – Sindicato da Indústria de Produtos Farmacêuticos no Estado de São Paulo elaborou este livro, MDCB – Manual das Denominações Comuns Brasileiras, em conjunto com a ANVISA contendo, na íntegra, os textos das Resoluções RDC n° 63, de 28 de dezembro de 2012 e RDC nº 64, de 28 de dezembro de 2012 que, respectivamente, definem os critérios de nomenclatura e a relação atualizada das Denominações Comuns Brasileiras vigentes. Este compêndio tem por escopo facilitar a consulta e utilização das DCBs, em complemento à versão eletrônica disponibilizada pela ANVISA. Com isso o SINDUSFARMA, coerente com a sua política de prover atualização dos temas técnico-regulatórios, edita este manual e o coloca à disposição dos profissionais do quadro associativo e do corpo de funcionários da ANVISA que atuam em áreas farmacêuticas.